Sanofi SA Earnings - Q2 2026 Analysis & Highlights
Sanofi's Q2 2026 earnings call focused on strong commercial momentum across its portfolio, strategic R&D transformation under new CEO Belén Garijo López, pipeline prioritization, and upgraded full-year guidance, while addressing challenges in pipeline productivity and the strategic importance of the Regeneron alliance.
Key Financial Results
Q2 net sales grew 17.8% to €11.6 billion, primarily driven by volume and including a couple of hundred million euros in positive gross-to-net adjustments.
Gross margin increased by 3.7 percentage points, benefiting from reversal of inventory provisions following Sarclisa SubQ regulatory approval, with underlying gross margin improvement of approximately 1.7 percentage points driven by favorable product mix and efficiency.
Operating expenses increased by 13.1%, primarily driven by Blueprint and Dynavax acquisitions, but excluding acquisition impact, OpEx grew at a moderate single-digit rate, with OpEx declining 1.5 percentage points as a percentage of sales.
Business operating income (BOI) increased by 35.8% with BOI margin expanding by 3.8 percentage points, driven by gross leverage, cost discipline, and favorable phasing of capital gains approximately €80 million higher than the prior year quarter, with underlying BOI growth around 20%.
Business EPS grew strongly at 33.3%, with underlying business EPS growth reaching 21% excluding share buyback and one-off items, supported by solid operational leverage.
H1 sales growth was 15.7% and business EPS was 22.7%, with underlying sales growth around 13%.
Business Segment Results
Pharma launches represented 13% of sales and grew over 60% in Q2, with sales from pharma launches up nearly 50%, led by Ayvakit, ALTUVIIIO, and Sarclisa.
Dupixent continued very strong growth at 37% in Q2, driven largely by volume with more patients receiving the treatment, and sales exceeded €5 billion in the quarter for the first time with more than 1.5 million patients currently under treatment globally.
Established medicines were stable in the quarter.
Vaccines declined slightly at 5% lower than last year, mainly impacted by a high comparable from last year's influenza sales, offset by solid Beyfortus and Heplisav-B performance, with vaccine sales reaching €1.15 billion in Q2.
Beyfortus sales grew 54% to €108 million, driven by a late US season and continued geographic expansion.
Heplisav-B grew 43% on a pro forma basis to €113 million, offsetting the expected impact of birth cohort dynamics of the pediatric franchise.
Rare disease sales reached nearly €1.9 billion, up 24%, driven by Ayvakit and ALTUVIIIO, with most medicines across the franchise growing in volume.
ALTUVIIIO continued strong momentum in hemophilia A and remains the top choice for patient switches in the US.
Ayvakit continues to expand in systemic mastocytosis, driven by continued growth in the number of patients treated and duration of treatment.
Sarclisa is performing well in multiple myeloma, with recent subcutaneous regulatory approval providing greater convenience for patients.
Capital Allocation
Sanofi is confirming its capital allocation principles, including commitment to the dividend and dividend policy.
Share buyback benefits are expected to be reduced in H2 2026 compared to H1.
The company invested €47 billion in BD and M&A over the last eight years, with €7 billion in losses and €40 billion in value creation from the remaining investments.
Industry Trends and Dynamics
Penetration of biologics across indications remains very low, reflecting significant opportunity for continued growth in immunology.
Dupixent remains the number one prescribed biologic across important prescriber groups in the US.
The rare disease market presents significant opportunity given Sanofi's top two or three market position and the breadth of the rare disease scope beyond rare genetic disorders.
China represents an extraordinary source of innovation with speed and ecosystem that is particularly interesting for pharmaceutical development.
US vaccination coverage rates have decreased, particularly for pediatric vaccines, impacting the vaccines business outlook.
Competitive Landscape
Dupixent faces tougher comparables in H2 2026 as newly launched indications annualize and comparables become tougher.
Recent competitor data supports confidence in the long-term potential of Amvuttra, a competing medicine in the same therapeutic area.
Frexalimab will need to demonstrate superiority over Aubagio in phase 3 studies for relapsing multiple sclerosis.
Macroeconomic Environment
Foreign exchange headwinds are impacting guidance, with the euro/dollar rate less favorable than when 2030 ambitions were originally set in 2023.
US VCR (vaccination coverage rate) evolution has turned out to be weaker than expected following the new US administration, primarily impacting respiratory vaccines.
The Chinese market operates differently than other countries with different pricing environments but attractive volumes from China-specific indications.
Growth Opportunities and Strategies
Dupixent 2030 ambition upgraded to around €25 billion in sales, reflecting continued strong momentum and growth across all indications.
Pharmaceutical launches ambition remains at €10 billion for 2030, reflecting the strength and diversity of the launch portfolio, with most products already in market representing primarily commercial risk.
Vaccine business expected to reach €9 billion in sales by 2030, thanks to differentiated portfolio and innovation, with €1 billion reduction from prior guidance split equally between currency impact and market dynamics.
Rare diseases represent a greater opportunity for Sanofi given strong capabilities and market leadership position, with plans to further build capabilities in the US and Europe, continue development in Japan, and expand presence in China.
China expansion is a priority with Thomas Triomphe, Head of Vaccines, nominated to lead China operations given the vibrant ecosystem and rapidly advancing science.
Regeneron alliance is of strategic importance with discussions ongoing to identify opportunities for further collaboration and rebuild trust to create a path forward for future collaboration.
Business development and M&A will be intensified in a disciplined way to enhance mid- and long-term growth prospects, with appetite for bigger deals subject to opportunity feasibility and strategic fit.
R&D transformation priorities include greater scientific rigor, fact-based decision-making, stronger governance, and more effective operations, with focus on balancing internal and external innovation to improve productivity.
Pipeline review is ongoing with focus on late-stage pipeline, prioritizing assets with highest scientific merit, highest unmet medical need, and highest potential.
Research efforts are already paying back with approximately one new phase 1 start planned every two months, representing a meaningful step-up in research productivity.
Pipeline and R&D Strategy
Several phase 3 studies did not achieve expected outcomes, including two studies of Dupixent in lichen simplex chronicus, the second venglustat study in Fabry disease, and riliprubart was stopped early in refractory CIDP based on IDMC recommendation.
Amlitelimab showed sustained response in ESTUARY long-term study but the company decided not to progress to regulatory submission as part of ongoing strategic assessment of the pipeline.
Nexviazyme met all study endpoints in infantile-onset Pompe disease, with 94% of infants alive and free from invasive ventilation at week 52.
Efdoralprin alfa demonstrated superiority over standard of care in achieving and maintaining normalized functional AAT levels in AATD emphysema, dosed every three weeks.
Venglustat received US priority review for type 3 Gaucher disease with a target action date of November 25.
Sarclisa subcutaneous formulation with on-body injector is now approved in major markets across different lines of treatment in multiple myeloma, designed to enable potential at-home administration.
Itepekimab programs across COPD and chronic rhinosinusitis have been discontinued.
Balinatunfib programs were discontinued after phase 2 studies in Crohn's disease and ulcerative colitis did not meet internal efficacy expectations.
Duvakitug will initiate two phase 2 studies in hidradenitis suppurativa and fibrostenotic Crohn's disease, complementing focus in inflammatory bowel disease.
Paulo Fontoura appointed as Head of R&D starting in September, described as an accomplished physician scientist with proven track record of leading large global organizations and advancing innovative pipeline.
Financial Guidance and Outlook
2026 sales growth guidance upgraded to around 10% at constant exchange rates with business EPS growing slightly faster than sales.
Vaccine sales growth expected to be slightly negative in 2026, mainly crystallizing in H2 due to usual seasonality, with Q3 specifically expecting low- to mid-teens sales decrease.
Tax rate for full year 2026 anticipated at around 21%, reflecting non-deductibility of certain impairment losses on intangible assets linked to recent pipeline decisions.
Q2 marks the end of Regeneron development balance reimbursement, with increase of Amvuttra royalties expected to fully offset this negative BOI impact for full year 2026.
2027 will see a negative €200 million BOI gap between Regeneron reimbursement ending and Amvuttra royalties increasing, with final negative BOI impact from Regeneron reimbursement of about €600 million year-on-year offset by Amvuttra royalties increase of about €400 million.
Amvuttra royalty projections through 2030 are based on Vara consensus, supporting confidence in long-term potential of the medicine.
H2 2026 expected to face tougher comparables with anticipated deceleration of sales growth due to lapping strong sales momentum from Dupixent's new indications and Ayvakit consolidation beginning July 2025.
Fewer one-off benefits to gross margin expected in H2 2026, with no further Regeneron development balance reimbursement and reduced benefits from share buyback.
Dupixent growth rate expected to moderate in H2 2026 as newly launched indications annualize and comparables become tougher.
Dupixent US approval in chronic spontaneous urticaria for children continues expansion of indication depth.
Multiple regulatory submissions and decisions anticipated based on data generated over coming years for medicines and vaccines already under review.
Expected phase 3 readouts include Sarclisa in transplant-eligible multiple myeloma in remainder of 2026, frexalimab in relapsing multiple sclerosis, riliprubart in CIDP compared to IVIg, and pneumococcal and yellow fever vaccines in 2027.
2028 expected to bring multiple phase 3 readouts for Wayrilz in IgG4-related disease and warm autoimmune hemolytic anemia, frexalimab in secondary progressive multiple sclerosis, and Sarclisa in smoldering multiple myeloma.
Dupixent Patent and Biosimilar Competition
Dupixent patent expiration date extends to 2046, with very strong patent portfolio around Dupixent from multiple innovations and nine indications to date.
Sanofi does not expect Dupixent to be protected beyond March 2031, with company taking a base case associated to loss of the product patent.
Company intends to vigorously defend Dupixent patents when typical patent fights commence.
Global Health and Access to Medicines
Sanofi Global Health Unit medicines now available in 30 underserved countries through impact, the non-for-profit brand of WHO essential medicines.
Target to reach 2 million patients suffering from non-communicable diseases by 2030 through global health initiatives.
Strategic partnership has reached 6.6 million beneficiaries with 6.5 million people screened, 1.1 million diagnosed, and nearly 0.5 million linked to care.
Over 40,000 healthcare professionals trained and more than 1,000 pharmacies and clinics supported through global health initiatives.
Executive Leadership Changes
Belén Garijo López joined as new CEO, marking her return to Sanofi after previous tenure, with focus on driving necessary improvement and leading organization in next phase of growth.
More focused executive committee announced with Paulo Fontoura joining as Head of R&D in September.
Three new ComEx members appointed from internal talent pipeline, including Manuela in Specialty Care, Jamie in General Medicine, and Thomas Triomphe leading China expansion.
